AU745055B2 - Parenterally administered medicament - Google Patents

Description

1.

Regulation 3.2

AUSTRALIA

Patents Act 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT

(ORIGINAL)

I

Name of Applicant: Actual Inventor: Address for Service: Invention Title: Delab of 51-53, rue du Docteur-Blanche, F-75016 Paris, France Roland CHERIF-CHEIKH DAVIES COLLISON CAVE, Patent Attorneys, 1 Little Collins Street, Melbourne, Victoria 3000.

"Parenterally administered medicament" The following statement is a full description of this invention, including the best method of performing it known to us: 1 *s r; b4

-A

P, P// P:\OPER\SSB\DELAB.DIV- 17/8/99 -2- PARENTERALLY ADMINISTERED MEDICAMENT Field of the Invention The present invention relates to a parenterally administered medicament for use in parenteral introduction devices and, in particular, to a device for intramuscular or subcutaneous administration of a pharmaceutically active composition.

Background of the Invention The parenteral route is preferred over oral ones in many occurrences. For example, when the drug to be administered would partially or totally degrade in the gastrointestinal tract, parenteral administration is preferred. Similarly, where there is need for rapid response in emergency cases, parenteral administration is usually preferred over oral.

Thus, while parenteral administration is desirable in many applications, as it is currently "practised, it presents substantial drawbacks. Probably the biggest drawback is the discomfort 15 which it causes the patient to whom the drug is being administered. Parenteral preparations generally contain a large volume of liquid in which the drug is suspended or dissolved. Ratios of active ingredient to carrier commonly run from 1:100 to 1:1000. Especially where the active ingredient is poorly soluble or difficult to suspend, or when it has to be administered at high doses, or in both instances, a fairly large volume of liquid must be injected. The injection of the needle and the introduction of a fairly large volume of liquid cause parenteral administration to be more or less painful and at least disagreeable, for most people. Furthermore, depending on its nature, the solvent or the suspending agent may itself be a cause of pain.

A further disadvantage to administration of drugs in a liquid carrier is that the drugs are frequently not stable in the liquid. Therefore, the liquid and drug must be mixed substantially contemporaneously with injection. This can be of substantial disadvantage where, for example, many hundreds of people must be treated over a course of days in order to stem an epidemic.

Accordingly, it would be interesting to find a mode of administration avoiding the use both of a needle and of a liquid solution or suspension.

Parenterally administered solid compositions for use in the controlled release of a medicament are known and devices allowing direct injection of a medicament without need of liquid are known such as, for example, trocars for implants of rods or pellets, and the device

F

4// P:\OPER\SSB\44542-99rs2.doc-17/01/02 -3shown in European Patent Application No. 0292936 A3 for injection of a solid. However, trocars and the device of European Patent Application No. 0292936 A3 still require use of a needle.

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.

Summary of the Invention The applicant has now discovered a comparatively inexpensive device for the ready 10 administration of solid or semi-solid drugs by the parenteral route. The applicant's device avoids completely the need for a needle.

The present invention provides a medicament adapted to be administered parenterally to a patient, said medicament comprising an active ingredient selected from the group consisting of growth hormone releasing peptide, luteinizing, hormone-releasing hormone, somatostatin, bombesin, gastrin releasing peptide, calcitonin, bradykinin, *galanin, melanocyte stimulating hormone, growth hormone releasing factor, amylin, tachykinins, secretin, parathyroid hormone, enkephalin, endothelin, calcitonin gene releasing peptide, neuromedins, parathyroid hormone related protein, glucagon, neurotensin, adrenocorticotrophic hormone, peptide YY, glucagon releasing peptide, factor 20 VIII, vasoactive intestinal peptide, pituitary adenylated cyclase activating peptide, motilin, substance P, neuropeptide Y, TSH, adrenaline, xylocaine, morphine, glucocorticoids, atropine, estrogen, androgen, interleukins, digitoxin, biotin, testosterone, heparin, cyclosporin, vitamins, antiplatelet activating factor agents, diazepam, D-Nal-cyclo[Cys- Tyr-D-Trp-Lys-Val-Cys]-Thr-NH 2 4, 7, 8, 10-tetrahydro-l-methyl-6-(2-chlorphenyl)-9- (4-methoxyphenyl-thiocarb amoyl)-pyrido-[4',3'-4,5]thieno[3,2-f] -1,2,4-triazolo[4,5-a] 1,4diazepine, ginkgolide B and decapeptyl and having a diameter of from 0.2 to 0.8 mm and a length of from 1 mm to 5 cm, and said medicament having sufficient structural integrity to penetrate the skin of the patient.

P:\OPERISSB"44542-99rcs2.doc- 17/01/02 -3A- One embodiment of the invention relates to a method of administering a medicament parenterally to a patient without the use of a needle, said method comprising bringing a medicament having a sufficient structural strength to penetrate the patient's skin into contact with the patient's skin and forcing the medicament through the skin.

Another embodiment of the invention relates to a medicament adapted to be administered parenterally, said medicament comprising at least about 10% active ingredient, said medicament having a diameter of from about 0.2 to about 2 mm and a length of from about 1 mm to about 5 cm, and said medicament having a crush strength of at least about 8 killipoise in the longitudinal direction.

S. 10 Another embodiment of the invention relates to a needle-less device capable of parenteral administration of a medicament, said device comprising a barrel member and a gas supply mechanism, said barrel member having first and second ends and a bore for receipt of said medicament in solid form, said bore extending from said first end to said second end of said barrel, said gas supply mechanism comprising a reservoir, a gas supply valve and an operating button, said operating button being depressible to allow gas to flow from said reservoir through said valve and into said barrel member, said gas being capable 0 2 0 0: il--lr" 11 11*^1 i-1 1 1111--- .li P:\op ssb\4454299n.doc-O8 05/01 -4of moving said medicament in said bore to push said medicament out said first end of the barrel member is pressed against the skin of the patient and said button is depressed and when the medicament is of sufficient structural strength to penetrate the skin of the patient.

Preferably, the medicament has sufficient structural strength so that it can penetrate through the skin into the subcutaneous layer when it is administered with the parenteral introduction device of an embodiment of the present invention. Thus, the drug penetrates the skin and there is no need for the expense of discomfort of a needle to administer the drug parenterally. Preferably, the present invention also includes an automatic device that can contain a number of doses of medicament which can be administered to a series of patients, one after the other.

Other features and advantages of the invention will be apparent from the following detailed description, made by way of example only, and with reference to the drawings.

~Brief Description of the Drawings 15 Fig. 1 is an exploded view of the parenteral introduction device according to an embodiment of the present invention; Fig. 2 shows the parenteral introduction device of an embodiment of the present invention in its retracted form; ••oeo Fig. 3 shows the device of an embodiment of the present invention with a medicament having been parenterally introduced into a patient; Fig. 4 shows the device of an embodiment of the invention with an automatic system where the plunger is replaced by a means for delivering pressurized gas; and go Fig. 5 shows an alternative embodiment of the automatic device for administering S•go seriatim shots to a number of individuals.

Detailed Description Referring first to Fig. 1, which is an exploded view of the parenteral introduction device of an embodiment of the present invention, there are three essential elements, namely a main barrel 10, a sleeve member 12, and a plunger member 14. The main barrel 10 has central bore 16 which extends from one end 22 to the other end 20 of the main h- jcz'arrel 10. A medicament 18 (see Fig. 2) is carried in this central bore 16. The main barrel

IU-

P:\opessb\44542-99rcs.doc8/05)01 -4Aincludes protruding ring members 24 and 26 which act as stops as will be hereinafter discussed. The sleeve member 12 is open at both its top 28 and bottom 30 ends. The sleeve member 12 includes shoulders 32 and 34 to limit travel of the sleeve as hereinafter discussed. Plunger member 14 includes a plunger rod 36 and an end cap 38. The end cap 38 has a circular plate member 40 and a toroidally .o S* **o o o oo P:\OPER\SSB\DELAB. DIV 17/8/99 shaped flange 42. The plunger rod 36 has an external diameter at least a portion of which is substantially the same as, or slightly smaller than, the internal diameter of the bore 16.

Fig. 2 shows the parenteral introduction device of Fig. 1 in assembled condition and in a condition suitable for transport and storage. Plunger member 14 is press fit onto the end 28 of sleeve 12. Sleeve 12 has been forced over main barrel 10 so that shoulder 32 has passed over ring member 24 and has come to rest against ring member 26. The sleeve member is in sliding engagement with the exterior surface of the main barrel 10. Abutment of shoulder 32 with ring member 26 restrains the relative position of the sleeve 12 and the main barrel 10 so that the plunger 14 does not inadvertently dislodge the medicament 18 and push it through the said one end 22 of the main barrel 10. Ring member 24 prevents the unintentional separation of sleeve 12 from main barrel 10 since it will engage shoulder 32 before the sleeve 12 and the main barrel are separated.

A seal 44 of biologically compatible material, such as cellulose or gelatin, may be applied to the end 22 of the main barrel 10 in order to maintain the sterility of the medicament 18 until it is administered. Alternatively, or additionally, the entire mechanism can be stored in a sterile environment such as a foil or cellophane pack (not shown).

Turning now to Fig. 3, there is shown an embodiment of the device in use. The said one end 22 of the main barrel 10 has been placed against the skin 48 of the patient to be treated, in such a way as to apply a tension on the zone where the medicament is to be injected. The plunger 14 and the sleeve 12, which travel together, have been urged down the main barrel by applying pressure on the end cap 38 of plunger 14 until shoulder 34 comes into contact with the ring member 24. The plunger rod 36 has traversed the length of the bore 16 of the main barrel 10 and has pushed the medicament 18 through the skin 48 of the patient and into the subcutaneous layer 46. Shoulder 34 of sleeve 12 in combination with ring member 24 of main barrel 10 has limited the extent of travel of the plunger rod 36 in the main barrel 10. It is preferred that the rod 36 of plunger member 14 stop no more than 2 mm below the said one end 22 of the main barrel 10 and it is most preferred that the plunger member not extend at all beyond the said one end 22 of the main barrel In Fig. 4, there is shown an alternative embodiment of the present invention. In an alternative embodiment, the plunger 14 is replaced by a means for providing gas pressure from a reservoir 52 and through a valve 54. The medicament 18 travels through barrel 56 under P:\OPER\SSB\DELAB.DIV- 17/8/99 -6pressure of the gas. Barrel 56 can be replaced for each new injection. When an injection is to be made, button 58 is depressed. This allows pressure to flow from reservoir 52 through valve 54 and regulator 60. The gas then forces the medicament 18 through the barrel 56 and into the patient (not shown). In the automatic device, this force is always the same because the amount of pressure exerted on the medicament is controlled by the regulator 60. Thus, the force of the injection is independent of any force applied by the operator.

In Fig. 5, there is disclosed an alternative embodiment of the automatic injector of Fig.

4. In this alternate embodiment, means are provided for injection of a plurality of doses to successive individuals using only a single injection device. This embodiment is illustrated in Fig. 5 where there is a magazine 62 which has a plurality of bores 64 with a medicament 18 fitted into each bore 64. As in the device of Fig. 4, gas pressure forces one of the medicaments 18 into a patient when button 58 is depressed. After delivery of the first medicament, the S. magazine 62 is moved to the left so that the next adjacent bore 64 and its associated medicament 18 are positioned above the barrel 56. The button 58 canbe depressed to create a new gas pressure and to inject this next medicament 18 into the next patient and thereafter the rest of •medicament 18 can similarly be administered seriatim to a series of individuals. Movement of the magazine can be effected manually or can be done automatically in a known manner.

All of the components of the device may suitably be made of plastic material, but it is preferred that the automatic device be made of metal, notably stainless steel. For the manual device, the plunger 36 can be made of metal, but it can also be made of plastic if its crosssection is increased sufficiently. Even where the plunger 36 is made of steel, it may be less S•expensive to make than the usual syringe since the device of the present invention does not require a stainless steel needle, the making of which requires quite a bit of precision. The main barrel 10 is preferably made with a nose cone shape at end 22. The main barrel can be made as a single piece, or, alternatively, the space between the outside wall 50 of the main barrel and wall of the central bore 16 can be hollow. The sleeve 12 is preferably made of transparent material so that the plunger rod 36 can be viewed therethrough, thus providing visual assurance that it is in its operative position.

The medicament 18 is preferably made of the shape of one end of a toothpick so that it can easily penetrate the skin and enter the subcutaneous layer. As is well known, one end of a toothpick has a point which tapers back to a cylindrical portion. The medicament is referred to c--I P:\OPER\SSB\DELAB.DIV 17/8/99 -7as solid; however, it may be either solid or semi-solid so long as it has sufficient structural integrity.to penetrate the skin without breaking apart. It has been found that a medicament having a crush strength of at least about 8 killipoise in the longitudinal direction is sufficiently strong, and lesser crush strengths are also usable, especially for administration to children, who have more tender skin than adults.

The amount of carrier in the medicament 18 depends on the drug and on the desired mode of action. As a general rule, the amount of active ingredient in the medicament is at least about 50%. With suitable medicaments which will have sufficient structural strength, the amount of medicament in the present invention can be up to 100%. The medicament may be prepared by conventional techniques such as compression, thermofusion, or extrusion.

Compression suitably consists of a tabletting process in which a toothpick-shaped microtablet is formed. Thermofusion suitably consists of mixing and melting of the active ingredients and a carrier, if desired. The melted product is then moulded into the toothpick-shaped oo:. medicament. Extrusion suitably consists of mixing the active ingredients and carrier, if desired, with a liquid to form a semisolid paste. The paste is then forced through a small diameter opening to form a rod. The needle-like tip can be formed prior to or after drying of the semisolid rods.

The size of the medicament 18 may be up to 2 mm in diameter but is preferably from about 0.2 mm to 0.8 mm, and most preferably from about 0.25 to 0.5 mm, in diameter for the cylindrical portion of the medicament, and about 1 mm to about 3 cm in length. The size will "•••"depend, of course, on the dose to be administered and the level of active ingredient present as ooo i compared to the amount of carrier.

The inside diameter of the bore 16 is preferably about 5-10% larger than the diameter of the medicament 18. This helps to ensure that the medicament does not get "hung up" or striated by minor imperfections, such as burrs, which may be introduced into the bore 16 during manufacture. At the same time, the diameter is limited to cause frictional engagement so that the medicament is less likely to be inadvertently dislodged from the bore prior to activation of the device. An oil can be added to the bore to increase the tendency of the medicament to remain in the bore; an oil will also assist in penetration through the skin.

The diameter of the medicament is not at all arbitrary; it has been found that the introduction of a pin with a diameter of about 2 mm or less is substantially painless. Such is not P:\OPER\SSB\DELAB.DIV- 17/8/99 -8the case for larger diameters, and larger diameter medicaments may general only be administered via a trocar.

The active ingredient can be a peptide or a protein. Examples of such peptides include growth hormone releasing peptide (GHRP), luteinizing hormone-releasing hormone (LHRH), somatostatin, bombesin, gastrin releasing peptide (GRP), calcitonin, bradykinin, galanin, melanocyte stimulating hormone (MSH), growth hormone releasing factor (GRF), amylin, tachykinins, secretin, parathyroid hormone (PTH), enkephalin, endothelin, calcitonin gene releasing peptide (CGRP), neuromedins, parathyroid hormone related protein (PTHrP), glucagon, neurotension, adrenocorticotrophic hormone (ACTH), peptide YY(PYY), glucagon releasing peptide (GLP), factor VIII, vasoactive intestinal peptide (VIP), pituitary adenylated cyclase activating peptide (PACAP), motilin, substance P, neuropeptide Y (NPY), TSH, and analogous and fragments thereof. Other active ingredients include insulin, adrenaline, :.xylocaine, morphine, a glucocorticoid dexamethasone), atropine, a cytostatic compound, estrogen, androgen, interleukins, digitoxin, biotin, testosterone, herapin, cyclosporin, penicillin, vitamins, antiplatelet activating factor agents ginkgolides), or diazepam.

In order to provide instant delivery of the active ingredient, the carrier should be water soluble. Examples of water soluble carriers include hyaluronic acid, cellulose, e.g., hydroxypropylmethyl cellulose (HPMC), carboxymethyl cellulose (CMC), and hydroxyethyl cellulose (HEC), polyalcohols, mannitol, sugars, dextrose, mannose, and glucose, gelatin, polyvinylpyrrolidone, and starches. The carrier can also be water insoluble, but o biodegradable to provide sustained delivery. Examples of suitable carriers include water insoluble polyesters of L-lactic acid, D-lactic acid, DL-lactic acid, L-lactide, D-lactide, DLlactide, glycolide, glycolic acid, capralactone, and any optically active isomers, racemates, or copolymers thereof.

The following are illustrative examples of the parenteral administration of drugs in solid form as compared to the conventional liquid form, and are intended to show that the two means of administration have similar pharmaceutical efficacy.

EXAMPLE 1 A test was conducted with Insulin Human Recombinant (IHR) and Insulin Bovine Pancreas (IBP). IHR is pure water soluble insulin; IBP is zinc insulin, water insoluble and P:\OPER\SSB\DELAB.DIV 17/8/99 -9prepared usually using 16% glycerol. IHR and IBP represent about 26 Insulin Units (IU) per mg.

Different doses of insulin were compared with a conventional injectable formulation.

In an in vivo test of hypoglycaemic effect on rats, all these formulations were found as effective in terms of intensity and rapidity of action.

Insulin can be delivered as a dry solid and acts exactly like the usual parenteral formulation for bolus injection. The quantities needed with the device of the present invention are small enough to be administered in solid form as a 2 mm long cylinder with a 0.45 mm diameter. Patients can readily perform virtually painless introduction of solid insulin with the device of the present invention. This form of insulin is also stable for a longer time at room *i temperature and less expensive than the usual liquid form.

EXAMPLE 2 A formulation of a somatostatin analogue, D-Nal-cyclo [Cys-Tyr-D-Trp-Lys-Val-Cys]- Thr-NH 2 was made into injectable tablets by associating the dry material with gelatin and polyvinylpyrrolidone (PVP, The tablets were injected and compared to conventional **solutions in terms of pharmacokinetic profiles. The methods gave substantially the same pharmacological results.

EXAMPLE 3 A synthetic anti-PAF, 4, 7, 8, 10-tetrahydro-l-methyl-6-(2-chlorphenyl)-9-(4methoxyphenyl-thiocarbamoyl)-pyrido-[4', 5] thieno 2, 2-triazolo 1,4diazepine, and a natural anti-PAF, ginkgolide B, were compared to conventional administration.

The synthetic anti-PAF cannot conventionally be used parenterally because of its insolubility.

Nevertheless, a very good correlation between pharmacological effect and blood concentration has been observed. Ginkgolide B is slightly soluble. For the same dose of product in solution form (pH 8.75), the effect was the same after initial injection but lasted only 2 hours with the solution whereas the effect lasted 24 hours with the solid dry formulation.

EXAMPLE 4 A prolonged formulation of decapeptyl (1 month) was made by a moulding process with P:\OPER\SSB\DELAB.DIV 17/8/99 a moulding machine into a shape of 0.8 mm diameter and some cm long.

Polylactidecoglycolide (PLGA, 80%) was used. The pharmacokinetically controlled delivery was equivalent to that of an implant or microspheres and the solid form was perfectly injectable subcutaneously or intravenously when the device was used in different species (rabbit, dog, rat, and pig).

Other Embodiments It will be understood that the claims are intended to cover all changes and modifications of the preferred embodiments of the invention herein chosen for the purpose of illustration which do not constitute a departure from the spirit and scope of the invention.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be S. understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

4 o «qp 2U": I 1 LI: I I~l-:f~

Claims (4)

1. A medicament adapted to be administered parenterally to a patient, said medicament comprising an active ingredient selected from the group consisting of growth hormone releasing peptide, luteinizing, hormone-releasing hormone, somatostatin, bombesin, gastrin releasing peptide, calcitonin, bradykinin, galanin, melanocyte stimulating hormone, growth hormone releasing factor, amylin, tachykinins, secretin, parathyroid hormone, enkephalin, endothelin, calcitonin gene releasing peptide, neuromedins, parathyroid hormone related protein, glucagon, neurotensin, adrenocorticotrophic hormone, peptide YY, glucagon releasing peptide, factor VIII, 1. 0vasoactive intestinal peptide, pituitary adenylated cyclase activating peptide, motilin, o. substance P, neuropeptide Y, TSH, adrenaline, xylocaine, morphine, glucocorticoids, atropine, estrogen, androgen, interleukins, digitoxin, biotin, testosterone, heparin, cyclosporin, vitamins, antiplatelet activating factor agents, diazepam, D-Nal-cyclo[Cys- Tyr-D-Trp-Lys-Val-Cys]-Thr-NH 2 4, 7, 8, 10-tetrahydro-l-methyl-6-(2-chlorphenyl)-9- (4-methoxyphenyl-thiocarb amoyl)-pyrido-[4',3'-4,5]thieno[3,2-f]-1 ,2,4-triazolo[4,5-a] 1,4- .diazepine, ginkgolide B and decapeptyl and having a diameter of from 0.2 to 0.8 mm and a length of from 1 mm to 5 cm, and said medicament having sufficient structural integrity to penetrate the skin of the patient.

2. The medicament of claim 1 wherein said medicament comprises substantially 100% active ingredient.

3. The medicament of claim 1 wherein the diameter of said medicament is from about 0.25 to about 0.50 mm.

4. The medicament of claim 1 wherein said medicament has the shape of a toothpick with a frustoconical point at one end thereof. (0 F\ Vgpn^ N:OPERVSMb44542-99res2. dmc-17/01/02 12 A medicament substantially as hereinbefore described with reference to the accompanying drawings and/or examples. DATED this 1 7 t1h day of January, 2002 DELAB 10 By its Patent Attorneys DAVIES COLLISON CAVE